Hypereosinophilic Syndromes (HES) are the group of rare disorders in which high numbers of eosinophils are found in the blood and tissue, for an extended period of time (6 months or more). In normal cases the blood eosinophil levels of less than 500/ml, people with HES typically have blood levels of more than 1,500/ml. The exact cause is not yet known but in some patient, FIP1L1/PDGFRA gene has been found in common. The continuous presence of a high number of eosinophil in the blood can eventually cause multiple organ tissue damage due to inflammation. If the disease is left untreated, it may be fatal.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hypereosinophilic-syndrome-market
The Hypereosinophilic Syndrome market report also covers emerging drugs, current treatment practices, Hypereosinophilic Syndrome market share of the individual therapies, current and forecasted Hypereosinophilic Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Hypereosinophilic Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Hypereosinophilic Syndrome Market Key Facts
-
Hypereosinophilic Syndromes (HES) is a rare disorder that causes an increased number of eosinophils in the blood and tissue, for a prolonged period of time.
-
The United States is observed to comprise the highest incident cases of Hypereosinophilic Syndrome in comparison to Europe and Japan.
-
As per the study by Baltazares-Lipp et al. titled, “Hypereosinophilic Syndrome: A Case of Fatal Löffler Endocarditis,” the exact epidemiology of HES is not known yet, but it is estimated that 90% of patients are men; the majority of the cases occur between 20–50 years of age, with a peak in the fourth decade of life. HES is a possibly fatal disease, with a survival rate of less than 50% after a 10-year follow-up.
-
According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Hypereosinophilic Syndrome
Key Benefits of Hypereosinophilic Syndrome Market Report
-
Hypereosinophilic Syndrome market report provides an in-depth analysis of Hypereosinophilic Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Hypereosinophilic Syndrome market report will help in developing business strategies by understanding the Hypereosinophilic Syndrome Market trends & developments, key players, and future market competition that will shape and drive the Hypereosinophilic Syndrome market in the upcoming years.
-
The Hypereosinophilic Syndrome market report covers Hypereosinophilic Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Hypereosinophilic Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Hypereosinophilic Syndrome Market
In the current scenario treatment of Hypereosinophilic Syndrome is unevenly distributed among the subsets and this yields an inadequate therapeutic coverage of some disease subgroups. In this respect, there is a need to discover other therapies for Hypereosinophilic Syndrome subsets with unmet therapeutic. The expected launch of different gene therapy shall fuel the Hypereosinophilic Syndrome market growth during the forecast period.
The Hypereosinophilic Syndrome market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Hypereosinophilic Syndrome market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Hypereosinophilic Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hypereosinophilic Syndrome Epidemiology
According to the study “World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management” by Gotlib et al. revealed there were 131 incident cases of Hypereosinophilic Syndrome between 2001–2005, the male‐to‐female ratio was 1.47, and the rates increased with the age of 65–74 years. Also, FIP1L1‐PDGFRA fusion occurs in approximately 10% of patients with idiopathic hypereosinophilia.
The Hypereosinophilic Syndrome epidemiology section covers insights about the historical and current Hypereosinophilic Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hypereosinophilic Syndrome Drugs Uptake and Key Market Players
The Hypereosinophilic Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypereosinophilic Syndrome market or expected to get launched in the market during the study period. The analysis covers Hypereosinophilic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Hypereosinophilic Syndrome market is anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world. At present some of the major players are diligently involved in developing therapies for Hypereosinophilic Syndrome.
Hypereosinophilic Syndrome Companies:
Novartis
AstraZeneca
GlaxoSmithKline
Knopp Biosciences
And others
Hypereosinophilic Syndrome therapies covered in the report include:
Benralizumab
Mepolizumab
Dexpramipexole
And many more
Table of Content
1. Key Insights
2. Executive Summary
3. Hypereosinophilic Syndrome Competitive Intelligence Analysis
4. Hypereosinophilic Syndrome Market Overview at a Glance
5. Hypereosinophilic Syndrome Disease Background and Overview
6. Hypereosinophilic Syndrome Patient Journey
7. Hypereosinophilic Syndrome Epidemiology and Patient Population
8. Hypereosinophilic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypereosinophilic Syndrome Unmet Needs
10. Key Endpoints of Hypereosinophilic Syndrome Treatment
11. Hypereosinophilic Syndrome Marketed Products
12. Hypereosinophilic Syndrome Emerging Therapies
13. Hypereosinophilic Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Hypereosinophilic Syndrome Market Outlook (7 major markets)
16. Hypereosinophilic Syndrome Access and Reimbursement Overview
17. KOL Views on the Hypereosinophilic Syndrome Market.
18. Hypereosinophilic Syndrome Market Drivers
19. Hypereosinophilic Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports By DelveInsight
Hypereosinophilic Syndrome Epidemiology Forecast
DelveInsight’s Hypereosinophilic Syndrome – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hypereosinophilic Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hypereosinophilic Syndrome Pipeline Insights
Hypereosinophilic Syndrome Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hypereosinophilic Syndrome market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/